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Background: Splicing is more efficient when coupled with transcription and it has been proposed that
nucleosomes enriched in exons are important for splice site recognition. Lynch syndrome is a familial cancer
syndrome that can be caused by the autosomal dominant inheritance of splice site mutations in the MutL
homolog 1 (MLH1) gene. To better understand the role of nucleosomes in splicing, we used MLH1 splice site
mutations in Lynch syndrome cases as a model to investigate if abnormal splicing was associated with altered
nucleosome positioning at exon-intron boundaries.
Findings: Nucleosome Occupancy and Methylome sequencing (NOMe-seq) was used to determine the allele-specific
positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines (LCLs) derived from
six Lynch syndrome patients. These mutations were previously shown to cause exon skipping in five of the six patients.
Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of
nucleosomes across all regions examined. Alleles containing donor or acceptor splice site mutations showed no
consistent alteration in nucleosome positioning or occupancy.
Conclusion: Nucleosomes were enriched at MLH1 exons in LCLs derived from Lynch syndrome patients, and in
this model system the positioning of nucleosomes was unaltered at exon-intron boundaries containing splice site
mutations. Thus, these splice site mutations alone do not significantly change the local organisation of nucleosomes.
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Background
Splicing removes introns from a longer pre-cursor RNA
molecule to produce a final processed mRNA. Splice
donor and acceptor sites located at the junctions be-
tween exons and introns contain conserved sequence
elements that are necessary for splicing [1]. Although
in vitro splicing can occur, splicing is more efficient when
coupled with transcription [2], suggesting that factors add-
itional to the nucleic acid sequence are important for
splice site recognition. It has been proposed that the posi-
tioning of nucleosomes at exons aids in splice-site recog-
nition [3,4].* Correspondence: robyn@unsw.edu.au
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unless otherwise stated.Nucleosome positioning describes the precise location
of a given nucleosome, whereas nucleosome occupancy
refers to the proportion of molecules bearing a nucleo-
some at a specific location, at any given instant [5]. It is
hypothesised that nucleosomes positioned within exons,
especially those with weak splice sites, cause RNA Poly-
merase II (RNAPII) to pause, enabling an interaction
with the spliceosome and more efficient splicing [3]. In
support of this, nucleosome occupancy is enriched
across exons [3,4], which have a high GC content that
favours nucleosome assembly [3,6], and the average size
of an exon within the body of a human gene is 151 bp,
that is similar in length to nucleosomal DNA (appro-
ximately 147 bp) [7]. Splicing factors associate with the
C-terminal domain of RNA Polymerase II (RNAPII) [8],
while the histone modification H3K36me3 is enriched in
exons [3,9], where it may act as a scaffold to recruit
splicing factors [9]. Taken together this indicates there isLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and the DNA sequence.
Lynch syndrome is an autosomal dominant familial
cancer syndrome characterised by early onset colorectal,
endometrial and other cancers [10,11]. It is most com-
monly caused by the inheritance of heterozygous loss-of-
function mutations, including splice site mutations, in the
DNA mismatch repair (MMR) genes MLH1 and MSH2
[12]. In this study we used MLH1 splice site mutations in
Lynch syndrome as a model to better understand the role
of nucleosomes in splicing. We investigated cells from
Lynch syndrome patients with splice site mutations to de-
termine whether splicing aberrations were associated with
altered nucleosome positioning at exon-intron boundaries.
Materials and methods
Identification of MLH1 splice site mutations
Bioinformatic analysis and in vitro assays previously
showed that genetic mutations at exon-intron boundaries
in the MLH1 gene generate aberrantly spliced transcripts
(see Table 1). All mutations were classified as pathogenic
(Class 5) according to the International Society for Ga-
strointestinal Hereditary Tumours Variant Interpretation
Committee (InSiGHT VIC) [12,13].
Cell culture
LCLs were established from patient blood by transform-
ation with Epstein-Barr Virus (as described previously)
[13], and cultured in RPMI with 10% fetal bovine serum
(Gibco, Life Technologies) at 37°C in 5% CO2. Lympho-
cytes for transformation from five patients (c.588 + 1G > T,
c.589-2A >G, c.791-1G >C, c.884G >A and c.1559-2A >T)
were obtained from the Australasian Colorectal Cancer







c.588 + 1G > T Chr. 3: 37,053,354 Donor Wild-type (G)
First bp of intron 7 Mutant (T)
Acceptor Homozygous
c.589-2A > G Chr. 3: 37,053,500 Acceptor Wild-type (A)
2nd last bp of intron 7 Mutant (G)
c.790 + 1G > T Chr. 3: 37,056,036 Donor Wild-type (G)
1st bp of intron 9 Mutant (T)
c.791-1G > C Chr. 3: 37,058,996 Acceptor Wild-type (G)
Last bp of intron 9 Mutant (C)
c.884G > A Chr. 3: 37,059,090 Donor Wild-type (G)
Last bp of exon 10 Mutant (A)
c.1559-2A > T Chr. 3: 37,081,675 Acceptor Wild-type (A)
Second last bp of intron 13 Mutant (T)patient with the c.790 + 1G > T mutation were obtained
from the MCO collection [15].
NOMe-seq
NOMe-seq was performed as described previously [16].
Briefly, intact nuclei were treated with 200 to 300 U
GpC methyltransferase M.CviPl and 160 to 320 μM
S-adenosylmethionine for 15 min at 37°C followed by
termination of the reaction with an equal volume of
20 mM Tris HCl pH 7.9, 600 mM NaCl, 1% (w/v) SDS
and 10 mM EDTA. DNA was extracted using phenol
chloroform followed by ethanol precipitation and bisul-
fite modified using the EZ DNA Methylation-Gold™ Kit
(Zymo Research). Regions incorporating the splice site
mutation in each patient were amplified from 40 ng
of bisulfite treated DNA using a nested PCR with the
primers and annealing temperatures described in Table 2.
Single molecule sequencing of PCR amplicons was perfor-
med as described previously [17]. Wild-type and mutant
alleles were distinguished using the splice site sequence
alteration. The M.CviPI enzyme methylates accessible
DNA at GpC sites, whereas nucleosome bound DNA is
inaccessible and remains refractory to GpC methylation.
Regions of M.CviPI inaccessibility of ≥150 bp (the length
of DNA wrapped around a single nucleosome) within a
single molecule were considered to represent regions of
nucleosome occupancy. In addition, NOMe-seq retains
the endogenous methylation status of the DNA allowing
nucleosome positions and DNA methylation to be deter-
mined on each molecule.
Results
We determined the positioning of nucleosomes across
exons 7, 8, 9, 10 or 14 of the MLH1 gene in LCLs derivedix individuals with Lynch syndrome
cclusion of splice site Splicing error [13]
Proportion of alleles
19/20 Exon 7 skipping (r.546_588del)
21/22
36/42




30/30 Exon 10 skipping (r.791_884del)
12/18
42/42 Exon 10 skipping (r.791_884del)
24/30
17/20 Two aberrant transcripts (Exon 14 skipping or
exon 14 and 15 skipping – r.[1559_1667del,
1559_1731del])16/16
Table 2 NOMe-seq primer sequences and amplification conditions
Region NOMe-seq primers Annealing (°C)
c.588 + 1G > T F:TTGATATTTAGTGTGTGTTTTTGGYAAT F/R = 54°C
R:CACATAATATCTTAAAAAATTCCAAAATAATA F/RN = 56°C
RN:ATACCRACTAACARCATTTCCAAAAATAA
c.589-2A > G F:TTAGGTATTTAGTATATAATGYAGG F/R = 51°C
R:CACTATAAATATTTTCAAAACTAAAACCTTA F/RN = 52°C
RN:CACAAAATCTAAAAAATTACATACACCTAA
c.790 + 1G > T F:TAGGYATAGGAGGATTTTAAATGGATTAAGTT F/R = 52°C
R:CAATTTCTTTAATAACAATRCCTATACCTAAA F/RN = 52°C
RN:TTACTCRTAAAAACTCTAACACCATCAA
c.791-1G > C F:GATGTGATGTGYATATTATTATAGAAATGTT F/R = 55°C
R:TATCARCACCTCCTAATAAAATGAARCATA F/RN = 56°C
RN:ATCCTTTTRCCAATAATATATAAAATTCACTCTA
c.884G > A F:GGATGTGATGTGYATATTATTATAGAAATGTT F/R = 58°C
R:CTATTATARCTTCCCAACTAACCCCARCAA F/RN = 58°C
RN:CTACAARCTATCARCACCTCCTAATAA
c.1559-2A > T F:TATTAGGAGGYTTAATTTAGGYTTTTTTGYTTAT F/R = 58°C
R:ACCCTCACCACCTAATTCACAACATTTATAA F/RN = 57°C
RN:ACTAARCAACTACCAAAAACTAARCTTCTTA
HSPA5 F: GAGAAGAAAAAGTTTAGATTTTATA F/R = 56°C
R: AAACACCCCAATAAATCAATC
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within or near these exons affected splice donor or ac-
ceptor sites (Table 1). NOMe-seq and single molecule
sequencing allowed us to distinguish mutant from wild-
type alleles using the splice site sequence mutation. At all
sites analysed the majority of molecules were inaccessible
at GpC sites and methylated at CpG sites (Figure 1).
NOMe-seq analysis of the control gene HSPA5, a consti-
tutively active gene that maintains a nucleosome-depleted
region at the transcription start site [18], showed that the
CpG island was unmethylated (data not shown) and con-
firmed that GpC inaccessibility was due to nucleosome
occupancy rather than incomplete M.CviPI treatment
(Figure 2). This shows that the majority of molecules
at the sites analysed are occupied by nucleosomes in
these cells.
Separation of alleles by presence or absence of the splice
site mutation showed no overall difference in either nu-
cleosome positioning or occupancy between wild-type and
mutant alleles (Figure 1 and Table 1). In the six splice site
mutations analysed, three were located within donor splice
sites and three were located within acceptor splice sites
(Table 1). Though some difference in precise positioning
between mutant and wild-type alleles was observed across
some exons (for example, exons 7 and 10, Figure 1B) this
was confined to a small subset of molecules, rather than
the majority of molecules as would be expected if themutations affected nucleosome positioning. Our study
therefore shows that nucleosome occupancy is unaltered
at exon-intron boundaries containing these splice site
mutations.
Discussion
In this study, we show that nucleosome positioning is
unaltered at exon-intron boundaries containing splice
site mutations. This finding suggests that the positioning
of nucleosomes at exon-intron boundaries containing
splice site mutations does not play a role in the splicing
defect.
NOMe-seq has been used to measure nucleosome
occupancy at gene promoters, CTCF binding sites [19]
and regulatory elements [20] but this is the first study
that has utilised the technique to measure nucleosome
occupancy at splice sites. NOMe-seq previously showed
that the active CpG island (CGI) promoter of HSPA5
has a nucleosome-depleted region (NDR) upstream of
the transcriptional start site [19]. This region was inclu-
ded as a control in each assay, and in all cases the NDR
was present. This indicated that the absence of GpC
methylation observed in MLH1 was caused by nucleo-
some occlusion, not an artefact caused by a defective M.
CviPI enzyme. In addition, CpG methylation was absent
from the HSPA5 NDR which is a feature of active CGI
promoters [21]. Finally, gene body methylation is a feature
Location of splice site mutations 
















































































Figure 1 Allele-specific positioning of nucleosomes at MLH1 variants. (A) The MLH1 gene with arrows showing the location of the splice
site mutations investigated in the LCLs derived from the six patients. The numbers correspond to the NOMe-seq assays shown in panel B (exon,
vertical bar; intron, horizontal bar with arrows). (B) Each panel shows the nucleosome occupancy on the wild-type allele (upper) and the allele
harbouring the indicated splice site mutation (lower). Blue box = exon; blue arrows = intron and direction of transcription; yellow diamond = location
of splice site mutation; vertical black bars below line = GpC sites; vertical black bars above line = CpG sites; the pink bar represents a single nucleosome
(150 bp, drawn to scale); pink shading indicates the location of nucleosomes on individual DNA molecules as determined by GpC methyltransferase
inaccessibility; black circles =methylated GpC/accessible to M.CviPI; white circles = unmethylated GpC/inaccessible to M.CviPI. CpG sites are depicted by
triangles. Black triangle =methylated CpG; white triangle = unmethylated CpG.
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Figure 2 Nucleosome occupancy and endogenous CpG methylation at the HSPA5 gene. (A) Schematic showing the location of the
NOMe-seq assay (black bar) in relation to the HSPA5 promoter. The arrow represents the transcriptional start site. (B) NOMe-seq was used to map
the position of nucleosomes on individual DNA molecules at the HSPA5 gene in LCLs derived from the six individuals with splice site mutations
in MLH1. Vertical black bars below line = GpC sites; vertical black bars above line = CpG sites; pink bars = the location of nucleosomes on individual
DNA molecules as determined by GpC methyltransferase inaccessibility; black circles =methylated GpC/accessible to M.CviPI; white circles = unmethylated
GpC/inaccessible to M.CviPI. All endogenous CpG sites were unmethylated and triangles are not shown to provide better clarity of GpC sites.
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within the MLH1 exons and introns were methylated. To-
gether, these controls indicated that the NOMe-seq assays
captured the true state of nucleosome positioning at
MLH1 splice sites.
Alternative splicing of MLH1 occurs in a range of nor-
mal tissues [24], but several pieces of evidence indicate
that the transcripts observed in our study are caused by
the mutation, rather than being normal splicing events.
First, the splicing aberrations were predicted with bio-
informatic splicing software [13], and second, although
one of the aberrant transcripts (Δ10) has been reported
among naturally occurring MLH1 splice transcripts, the
clinical data associated with these variants are alsoindicative of pathogenicity as demonstrated by the results
of previous multifactorial likelihood analyses [13].
One strength of our study was the ability to determine
the allele-specific position of nucleosomes by incorporat-
ing a heterozygous single nucleotide variant into each
NOMe-seq assay. Small changes in positioning were ob-
served but these molecules constituted approximately
the same small proportion of total molecules on both
alleles. Subtle changes in nucleosome positioning have
been considered important in regulating the expression
of cell cycle-dependent genes [18] and enhancer accessi-
bility [25], but in those studies the subtle changes were
observed on a significant number of molecules that re-
sulted in an overall change in nucleosome occupancy.
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pancy between the wild-type and mutant alleles at a
variety of donor and acceptor sites, which would be
expected if nucleosome positioning at these sites played
a role in mediating the effects of splice site mutations.
Together our data shows that alleles containing a splice
site mutation show no differences in nucleosome occu-
pancy to wild-type alleles.
A limitation of the approach was that in most of the
assays (assays 2 to 6) it was only possible to measure nu-
cleosome positions at either the donor site or the acceptor
site. Bisulfite conversion causes fragmentation of genomic
DNA and it is technically challenging to amplify fragments
greater than 500 bp in length [26]. The donor and accep-
tor sites were separated by more than 2 kb of intronic
sequence, making it impossible to concurrently determine
the allele-specific position of nucleosomes at the donor
and acceptor site on the same molecule. Although an
independent NOMe-seq assay could be performed at the
other donor or acceptor site, it would provide no informa-
tion on allele-specificity. The data from one assay (c.588 +
1 G > T), however, in which both splice sites were present
in the one amplicon, showed no significant change in
nucleosome occupancy at the donor or acceptor site
in intron 7.
Previous studies have utilised genome-wide datasets
of micrococcal nuclease (MNase) digested chromatin to
investigate nucleosome occupancy [3,4]. Here we used
NOMe-seq to map the position of nucleosomes relative to
exons and splice sites in a single gene at single molecule
resolution. This approach provides the most accurate pos-
sible measurement of nucleosome positioning and enables
allele-specific mapping of nucleosomes. In agreement with
previous reports in humans [3,4], Caenorhabditis elegans
[3,4] and Drosophila melanogaster [3], we observed high
nucleosome occupancy at exons. Thus, the findings from
genome-wide studies were supported by our independent,
single-molecule approach at the MLH1 gene.
A key finding of our study was that nucleosome posi-
tioning was not significantly affected by mutations at
the MLH1 splice sites investigated. Recent work with an
in vitro IKBKAP mini-gene system found that alterna-
tive splicing changed chromatin organisation, with splice
site strength and factors needed for splicing, such as U1
snSNP, playing a role in the regulation of nucleosome
occupancy in exons [27]. This and an earlier study [3] in-
dicate that splice site strength is an important determinant
of nucleosome occupancy in exons. Exons with stronger
polypyrimidine tracts (PPT; one of the conserved DNA
elements located at 3′ splice sites) have increased nucleo-
some occupancy compared to immediately adjacent in-
trons, suggesting that nucleosomes act as a barrier that
help to define the physical location of the 3′ splice site [3].
Although we investigated an equal number of donor andacceptor splice site mutations, nucleosome positioning
was not significantly different between exons and the im-
mediate 5′ and 3′ intronic sequence on the wild-type or
mutant allele. The discrepancy between earlier studies and
ours may in part relate to the strength of the MLH1 splice
sites investigated. Alternatively, changes to chromatin or-
ganisation induced by splice mutations may be different to
those caused by normal splicing events. Co-transcriptional
splicing involves a complex interplay between RNAPII,
the spliceosome [8] and histone modifications [3,9] and
alterations in these factors, in addition to DNA sequence
changes may be needed to alter nucleosome occupancy
at exons.
In summary this study used NOMe-seq to determine
the allele-specific position of nucleosomes in relation to
MLH1 splice site mutations. We conclude that splice site
mutations that cause aberrant splicing of MLH1 do not
alone significantly affect local nucleosome positioning in
LCLs from Lynch syndrome patients.
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